Compare · IMAX vs TMO
IMAX vs TMO
Side-by-side comparison of Imax Corporation (IMAX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- IMAX operates in Consumer Discretionary, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 91.1x IMAX ($2.83B).
- Over the past year, IMAX is up 61.0% and TMO is up 28.5% - IMAX leads by 32.4 points.
- TMO has been more active in the news (7 items in the past 4 weeks vs 2 for IMAX).
- TMO has more recent analyst coverage (25 ratings vs 13 for IMAX).
- Company
- Imax Corporation
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $2.83B
- $257.53B
- 1M return
- -1.95%
- +4.77%
- 1Y return
- +60.98%
- +28.53%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 2
- 7
- Recent ratings
- 13
- 25
Imax Corporation
IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company worldwide. It offers cinematic solution comprising proprietary software, theater architecture, intellectual property, and specialized equipment. The company offers IMAX Digital Re-Mastering (DMR), a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of motion picture films for projection on IMAX screens; IMAX theater systems to exhibitor customers through sales, leases, and joint revenue sharing arrangements; digital projection systems; a digital theater control systems; and a digital audio systems. It also provides proactive and emergency maintenance services to the IMAX network; licenses film content and distributes large-format documentary films; film post-production and quality control services for large-format films, and digital post-production services; owns and operates IMAX theaters; and rents 2D and 3D large-format film and digital cameras, as well as offers production advice and technical assistance services to documentary and Hollywood filmmakers. The company markets its theater systems through a direct sales force and marketing staff to science and natural history museums, zoos, aquaria, and other educational and cultural centers, as well as theme parks, private home theaters, tourist destination sites, fairs, and expositions. It owns or otherwise has rights to trademarks and trade names, which include IMAX, IMAX Dome, IMAX 3D, IMAX 3D Dome, Experience It in IMAX, The IMAX Experience, An IMAX Experience, An IMAX 3D Experience, IMAX DMR, DMR, IMAX nXos, and Films To The Fullest. As of December 31, 2020, the company had a network of 1,650 IMAX theater systems comprising 1,562 commercial multiplexes, 12 commercial destinations, and 76 institutional facilities operating in 81 countries and territories. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest IMAX
- SEC Form 4 filed by Chief Commercial Officer & EVP Dolci Giovanni M.
- Morgan Stanley initiated coverage on IMAX with a new price target
- Chief Legal Officer Sr Exec VP Lister Robert D sold $1,160,577 worth of shares (22,500 units at $51.58), decreasing direct ownership by 11% to 182,375 units (SEC Form 4)
- IMAX Soars to Highest Grossing Summer Ever with $728 Million Worldwide — Up 73% Over Previous Record
- President IMAX Global Theatres Welton Mark sold $1,634,208 worth of shares (30,000 units at $54.47), decreasing direct ownership by 17% to 143,216 units (SEC Form 4)
- Deputy GC, Corp. Sec. & CCO Weissman Kenneth Ian sold $436,294 worth of shares (8,000 units at $54.54), decreasing direct ownership by 22% to 28,205 units (SEC Form 4)
- Chief Financial Officer & EVP Fernandes Natasha sold $1,092,554 worth of shares (20,000 units at $54.63), decreasing direct ownership by 36% to 35,596 units (SEC Form 4)
- IMAX to Present at Upcoming Institutional Investor Conferences
- Imax Corporation filed SEC Form 8-K: Leadership Update
- CTO & EVP Pablo Calamera sold $786,174 worth of shares (15,000 units at $52.41), decreasing direct ownership by 26% to 43,012 units (SEC Form 4)
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)